Navigation Links
Genaera to Present at BIO-Europe 2008
Date:11/13/2008

PLYMOUTH MEETING, Pa., Nov. 13 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) will present at BIO-Europe 2008 being held November 17-19 at the Congress Center in Mannheim, Germany. Dr. Henry Wolfe, Executive Vice President and Chief Scientific Officer, will present a company overview on Tuesday, November 18, 2008 at 11:00 a.m. CET.

About Genaera

Genaera Corporation is developing trodusquemine (MSI-1436) for type 2 diabetes and obesity currently in phase 1 clinical testing and has a fully out-licensed partnership with MedImmune, Inc. that is in phase 2 clinical testing in asthma. For further information, please see our website at http://www.genaera.com.

This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, known and unknown. Forward-looking statements reflect management's current views and are based on certain expectations and assumptions. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "believe," "continue," "develop," "expect," "plan" and "potential" or other words of similar meaning. Genaera's actual results and performance could differ materially from those currently anticipated and expressed in these and other forward-looking statements as a result of a number of risk factors, including, but not limited to the risks and uncertainties discussed in Genaera's filings with the U.S. Securities and Exchange Commission, all of which are available from the Commission in its EDGAR database at http://www.sec.gov as well as other sources. You are encouraged to read these reports. Given the uncertainties affecting development stage pharmaceutical companies, you are cautioned not to place undue reliance on any such forward-looking statements, any of which may turn out to be wrong due to inaccurate assumptions, unknown risks, uncertainties or other factors. Genaera does not intend (and it is not obligated) to publicly update, revise or correct these forward-looking statements or the risk factors that may relate thereto.


'/>"/>
SOURCE Genaera Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Genaera Elects New Board Member and Announces Executive Appointments
2. Genaera to Present at Biotech 2007 and BIO InvestorForum
3. Genaera Corporation Announces Third Quarter Financial Results
4. Genaera Corporation to Participate in Diabetes and Obesity Panel at RBC Capital Markets Healthcare Conference
5. Genaera Corporation Announces 2007 Financial Results
6. Genaera Corporation Announces First Quarter Financial Results
7. Genaera Corporation to Present at BIO Business Forum
8. Genaera Corporation Elects Paul K. Wotton to Board of Directors
9. Genaera Corporation Announces Second Quarter Financial Results
10. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
11. Avicena Group to Present at Noble Financial Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Feb. 11, 2016  Dovetail Genomics™ LLC today announced ... program for a planned metagenomic genome assembly service. ... metagenomic genome assembly method in a talk on Friday, ... & Technology conference in Orlando, Fla. ... complex datasets is difficult. Using its proprietary ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... medicine, has announced a new agreement with Bankok,Thailand-based Global Stem Cells Network (GSCN) ... phsyicians in 15 Latin American countries, including Mexico, Costa Rica, Dominican Republic, Colombia, ...
(Date:2/10/2016)... , Feb. 10, 2016  The Maryland House ... , has announced that University of Maryland School of ... MBA and University of Maryland Medical System President and ... the "Speaker,s Medallion," the highest honor given to the ... Delegates. Dean Reece and Mr. Chrencik ...
(Date:2/10/2016)... Inc. (NYSE MKT: ISR), a medical technology company and ... the treatment of prostate, brain, lung, head and neck ... the second quarter and six months of fiscal 2016, ... --> --> Revenue was $1.19 million ... December 31, 2015, a 12% increase compared to $1.07 ...
Breaking Biology Technology:
(Date:2/11/2016)... 11, 2016  Vigilant Solutions announces today that its license ... used by Lee,s Summit Police Department ... and arrest of a homicide suspect. Kansas ... around 65 square miles and is home to roughly 100,000 ... a single mobile license plate reader system and also leverages ...
(Date:2/9/2016)... , Feb. 9, 2016 Vigilant Solutions announces today ... reader (LPR) to develop a lead in a difficult homicide ... LPR data to locate the suspect vehicle. Due to the ... case have been omitted at the agency,s request. ... agency explains, "Our victim was found deceased at an intersection ...
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... is apparently one of the most popular hubs ... Project, MetaHIT and other huge studies of human ... that past few years, the microbiome space has ... applied biomedical research. This report focuses on ...
Breaking Biology News(10 mins):